Article
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study.
Clinical colorectal cancer - 1 Dec 2024
Chen Yijiao, Zhu Dexiang, Yu Yiyi, Chang Wenju, Ye Lechi, Feng Qingyang, Xu Pingping, Chen Miao, Ji Meiling, Wei Ye, Liu Tianshu, Xu Jianmin
Abstract excerpt
BACKGROUND: Colorectal cancers (CRC) with BRAF V600E mutation exhibit limited chemotherapy response and a poor prognosis. Safety and efficacy of the VIC (Vemurafenib/Irinotecan/Cetuximab) regimen in the first-line setting for patients with BRAF V600E-mutated CRC remain undetermined. METHODS: In the prospective cohort study, the untreated, BRAF V600E-mutated, unresectable or metastatic CRC patients were enrolled....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.